Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases [1]
This phase II trial evaluated outcomes of isolated lung perfusion with Melphalan and complete surgical resection for pulmonary metastases from colorectal cancer or sarcoma in 50 pts. Surgical mortality was 0%, but morbidity (primarily grade 3 or 4 pulmonary morbidity) was 44%. 30 patients suffered local recurrence. 3-year survival was 57% and recurrence-free survival was 36%.